Brief: Akari Therapeutics Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirement

Akari Therapeutics

25/04/2023 22:12

Akari Therapeutics PLC  AKTX.O :
    * AKARI THERAPEUTICS GRANTED 180-DAY EXTENSION BY NASDAQ TO
MEET
MINIMUM BID PRICE REQUIREMENT

Source text for Eikon:  ID:nGNEc1SW7p 
Further company coverage:  AKTX.O